

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUNPHARMA **复星医药**

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

INSIDE INFORMATION AND RESUMPTION OF TRADING

This announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board (“**Board**”) of directors (“**Directors**”) of the Company has noted that recent media coverage published on WeChat public platform (the “**News**”) that Sinopharm Holding GuoDa Drug Store Co., Ltd.* (國藥控股國大藥房有限公司) (“**GuoDa Drug Store**”), a wholly owned subsidiary of Sinopharm Group Co., Ltd.* (國藥控股股份有限公司), a company listed on the Hong Kong Stock Exchange (Stock code: 01099) intends to acquire (the “**Proposed Transactions**”) equity interests in Shanghai For Me Yixing Pharmacy Chain-Store Company Limited* (上海復美益星大藥房連鎖有限公司) (“**For Me Pharmacy**”), and Beijing Golden Elephant Pharmacy Medicine Chain Company Limited* (北京金象大藥房醫藥連鎖有限責任公司) (“**Golden Elephant Pharmacy**”), both are non-wholly-owned subsidiaries of the Company. In order to verify the aforesaid News, at the request of the Company, trading in the H shares of the Company on the Hong Kong Stock Exchange has been halted with effect from 9:02 a.m. on Thursday, 27 November 2014.

After verification, to the best of knowledge and information of the Directors and having made all reasonable enquiries, as at the date of this announcement, the Company is still in negotiations with GuoDa Drug Store in relation of the Proposed Transactions, and the same would also be subject to the approval by the relevant state-owned assets supervision and administration authority. Based on the current proposals, it is expected that if the transfers are to take place, they will have no significant impact on the earnings of the Company and its subsidiaries (the “**Group**”), as the proceeds from the transfers will be used in the development of other major businesses of the Group. Shareholders and potential investors should note that there is no assurance that the Proposed Transactions will proceed.

The Company will fulfill its obligations of information disclosure in a timely manner and will make further announcement on the progress of the Proposed Transactions under the applicable laws and regulations as and when necessary.

At the request of the Company, trading in the H shares of the Company on the Hong Kong Stock Exchange has been halted with effect from 9:02 a.m. on Thursday, 27 November 2014 pending the release of this announcement. An application has been made by the Company to the Hong Kong Stock Exchange for the resumption of trading in the H shares of the Company with effect from 9:00 a.m. on Friday, 28 November 2014.

Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co. Ltd.*
Chen Qiyu
Chairman

Shanghai, PRC
27 November 2014

As at the date of this announcement, the executive Directors are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive Directors are Mr. Han Jiong, Dr. Zhang Weijiong, Mr. Li Man-kiu Adrian David and Mr. Cao Huimin.

* *for identification purposes only*